These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25498056)

  • 1. Retrospective evaluation of the effect of mycophenolate mofetil dosage on survival of kidney grafts based on biopsy results.
    Ji SM; Xie KN; Chen JS; Wen JQ; Cheng DR; Li X; Ni XF
    Transplant Proc; 2014 Dec; 46(10):3383-9. PubMed ID: 25498056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
    Squifflet JP; Bäckman L; Claesson K; Dietl KH; Ekberg H; Forsythe JL; Kunzendorf U; Heemann U; Land W; Morales JM; Mühlbacher F; Talbot D; Taube D; Tyden G; van Hooff J; Schleibner S; Vanrenterghem Y;
    Transplantation; 2001 Jul; 72(1):63-9. PubMed ID: 11468536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
    Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.
    Gourishankar S; Houde I; Keown PA; Landsberg D; Cardella CJ; Barama AA; Dandavino R; Shoker A; Pirc L; Wrobel MM; Kiberd BA
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1282-9. PubMed ID: 20498245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose.
    Kocak H; Yakupoglu U; Karatas GU; Yavuz A; Gurkan A; Erdogan O; Ersoy FF; Yakupoglu G; Demirbas A; Tuncer M
    Transplant Proc; 2005 Sep; 37(7):3009-11. PubMed ID: 16213288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.
    Sampaio EL; Pinheiro-Machado PG; Garcia R; Felipe CR; Park SI; Casarini DE; Moreira S; Franco MF; Tedesco-Silva H; Medina-Pestana JO
    Clin Transplant; 2008; 22(2):141-9. PubMed ID: 18339132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy.
    Schwarz C; Regele H; Huttary N; Wahrmann M; Exner M; Nagy-Bojarsky K; Kletzmayr J; Hörl WH; Böhmig GA
    Wien Klin Wochenschr; 2006 Jul; 118(13-14):397-404. PubMed ID: 16865644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
    Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
    Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
    Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
    Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.
    Moreso F; Serón D; Morales JM; Cruzado JM; Gil-Vernet S; Pérez JL; Fulladosa X; Andrés A; Grinyó JM
    Clin Transplant; 1998 Jun; 12(3):198-205. PubMed ID: 9642510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.